Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

806.52 +43.52 (+5.70%)
Streaming Delayed Price Updated: 11:06 AM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
IPO Stock Hinge Health Surges Despite Lackluster Second-Quarter Sales
The company, which went public in May, provides AI-powered physical therapy through a mobile application. 
Via Investor's Business Daily
Topics Initial Public Offering
Inspire Medical Plunges On Outlook Cut, Weak V System Rollout: Analysts React
Inspire Medical stock falls as Q2 earnings beat is overshadowed by guidance cut and slower U.S. rollout of its newly approved Inspire V system. 
Via Benzinga
Topics Earnings
Why Novo Nordisk Stock Is Down Again Today
Are you brave enough to catch this falling knife? 
Via The Motley Fool
The 8 Best Stocks to Buy Now in August (2025)
Whether you're looking for growth stocks, dividend stocks, or artificial intelligence stocks, there is something for you in this incredible list. 
Via The Motley Fool
Topics Artificial Intelligence
Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance
The company makes implantable devices for sleep apnea, an area Eli Lilly is marketing its weight-loss drug. 
Via Investor's Business Daily
Novo Nordisk Stock Sinks—But Is a Bottom Finally In?
Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings 
Via MarketBeat
Eli Lilly Reverses Early Weakness, Closes Near Day's High After Key Trading Signal
A significant trading signal flashed for Eli Lilly (LLY) at a price of $755.87, after which LLY rose up to 1.8% and closed near its intra-day high. 
Via Benzinga
Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?
Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations. 
Via Benzinga
Prediction: This Unstoppable Growth Stock Will Be Worth $2 Trillion in the Next 7 Years
It's not too late to invest in this company. 
Via The Motley Fool
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity
 
Via Benzinga
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
Stock Market Today: US Stocks Likely To Open Higher Despite Weak Jobs Report—Palantir, Vertex Pharma In Focus
US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics. 
Via Benzinga
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
3 Unstoppable Stocks to Buy in August
Here are hot stocks to buy in a hot month. 
Via The Motley Fool
Topics Intellectual Property
Why Eli Lilly Stock Topped the Market Today
Zepbound could benefit handsomely if an apparently planned government program is implemented. 
Via The Motley Fool
Topics Government
Why Novo Nordisk Stock Bumped Higher on Friday
There might be a new way for certain users to defray their costs for obesity treatments. 
Via The Motley Fool
Topics Government
Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic
pheton-holdings-dismisses-rumors-of-acquisition-by-gilead 
Via Stocktwits
Topics Government
Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under Medicaid, Medicare
The Washington Post reported on Friday that state Medicaid programs and Medicare Part D insurance plans will be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro, and Zepbound for patients... 
Via Stocktwits
Topics Government
Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients
The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy under Medicare and Medicaid programs. 
Via Benzinga
Topics Government
3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double
These pharmaceutical giants are well worth a second look. 
Via The Motley Fool
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Trump To Issue 60-Day Warning Letters To Drugmakers Over Pricing
The U.S. President is expected to send out these letters through his social media platform, Truth Social. 
Via Stocktwits
Topics Government Regulatory Compliance
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
Should You Buy Pfizer (PFE) Stock Before August 5? Here's What History Says
Pfizer presents a good buying opportunity, but not because of potential earnings. 
Via The Motley Fool
Topics Supply Chain
Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health
Eli Lilly's Mounjaro matched Trulicity in heart outcomes and showed added benefits on A1C, weight, kidney function, and mortality in a major trial. 
Via Benzinga
Novo Nordisk Hit With Stock Downgrades After Lowering Full-Year Outlook: But Retail Is Optimistic On Company’s Profitability
Barclays downgraded Novo to ‘Equal Weight’ from ‘Overweight’ with a price target of DKK 375, down from DKK 700. 
Via Stocktwits
Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session. 
Via Benzinga
Why Eli Lilly Stock Was Looking Sickly Today
It seemed the market overreacted to discouraging news from one of the company's rivals. 
Via The Motley Fool
History of Novo Nordisk A/S Stock: From Insulin Pioneers to Global Pharma Leader (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) has evolved over the past century from a humble insulin manufacturer in Denmark into one of the world’s most valuable pharmaceutical companies. With a commanding presence in... 
Via MarketMinute
Topics Economy Emissions
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS